Literature DB >> 15935875

Viral vectors for use in the development of biodefense vaccines.

John S Lee1, Angela G Hadjipanayis, Michael D Parker.   

Abstract

The heightened concerns about bioterrorism and the use of biowarfare agents have prompted substantial increased efforts towards the development of vaccines against a wide range of organisms, toxins, and viruses. An increasing variety of platforms and strategies have been analyzed for their potential as vaccines against these agents. DNA vectors, live-attenuated viruses and bacteria, recombinant proteins combined with adjuvant, and viral- or bacterial-vectored vaccines have been developed as countermeasures against many potential agents of bioterrorism or biowarfare. The use of viruses, for example adenovirus, vaccinia virus, and Venezuelan equine encephalitis virus, as vaccine vectors has enabled researchers to develop effective means for countering the threat of bioterrorism and biowarfare. An overview of the different viral vectors and the threats they counter will be discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15935875     DOI: 10.1016/j.addr.2005.01.011

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  7 in total

1.  Rescue from cloned cDNAs and in vivo characterization of recombinant pathogenic Romero and live-attenuated Candid #1 strains of Junin virus, the causative agent of Argentine hemorrhagic fever disease.

Authors:  Sebastien F Emonet; Alexey V Seregin; Nadezhda E Yun; Allison L Poussard; Aida G Walker; Juan C de la Torre; Slobodan Paessler
Journal:  J Virol       Date:  2010-12-01       Impact factor: 5.103

Review 2.  Arenavirus reverse genetics: new approaches for the investigation of arenavirus biology and development of antiviral strategies.

Authors:  Sebastien E Emonet; Shuzo Urata; Juan C de la Torre
Journal:  Virology       Date:  2011-02-15       Impact factor: 3.616

3.  A nonhuman primate scrub typhus model: protective immune responses induced by pKarp47 DNA vaccination in cynomolgus macaques.

Authors:  Daniel H Paris; Suchismita Chattopadhyay; Ju Jiang; Pruksa Nawtaisong; John S Lee; Esterlina Tan; Eduardo Dela Cruz; Jasmin Burgos; Rodolfo Abalos; Stuart D Blacksell; Eric Lombardini; Gareth D Turner; Nicholas P J Day; Allen L Richards
Journal:  J Immunol       Date:  2015-01-19       Impact factor: 5.422

4.  Efficacy of Western, Eastern, and Venezuelan Equine Encephalitis (WEVEE) Virus-Replicon Particle (VRP) Vaccine against WEEV in a Non-Human Primate Animal Model.

Authors:  Crystal W Burke; Rebecca A Erwin-Cohen; Aimee I Goodson; Catherine Wilhelmsen; Jennifer A Edmundson; Charles E White; Pamela J Glass
Journal:  Viruses       Date:  2022-07-08       Impact factor: 5.818

Review 5.  Malaria vaccine adjuvants: latest update and challenges in preclinical and clinical research.

Authors:  Elena Mata; Aiala Salvador; Manoli Igartua; Rosa María Hernández; José Luis Pedraz
Journal:  Biomed Res Int       Date:  2013-04-23       Impact factor: 3.411

6.  Transcriptomic profiles of high and low antibody responders to smallpox vaccine.

Authors:  R B Kennedy; A L Oberg; I G Ovsyannikova; I H Haralambieva; D Grill; G A Poland
Journal:  Genes Immun       Date:  2013-04-18       Impact factor: 2.676

Review 7.  Vaccines against Botulism.

Authors:  Grace Sundeen; Joseph T Barbieri
Journal:  Toxins (Basel)       Date:  2017-09-02       Impact factor: 4.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.